7.35.3 NMAC · Training & Education

Published August 25, 2026 · the current proposed rule · rule hearing October 2, 2026

The published rule

The full text of 7.35.3 NMAC as published August 25, 2026, all twenty-eight sections, with the state of each contested provision noted where it lives. This text supersedes the set-aside July 23 publication and goes to hearing on October 2, 2026; public comment continues through the hearing. The rule’s definitions are in amendments to 7.35.2.7 NMAC published the same day. Line breaks are collapsed for reading; where the extraction stumbles, the linked PDF governs.

Text from the official PDF published August 25, 2026. Regenerated by tools/build-rule-page.py.

.1 Issuing Agency .2 Scope .3 Statutory Authority .4 Duration .5 Effective Date .6 Objective .7 Definitions Note2.7 The Definitions The Rule Runs On Open Note.8 Patient Enrollment Application Process .9 Certifying Clinician, Practitioner, And Facilitator Application Process Settled.10 Application Process For Certification As A Certifying Clinician, Practitioner, Or Facilitator Based On Educational Programs From Other Jurisdictions Settled.11 Application Process For Healing Centers And Other Approved Locations Open.12 Application Process For Psilocybin Educational Programs .13 Requirements And Prohibitions For Certifying Clinicians, Practitioners, And Facilitators Note.14 Authorized Possession, Purchase, Or Sale Of Medical Psilocybin By Practitioners, Facilitators, Healing Center Owners And Employees; Chain Of Custody Defect Note.15 Psilocybin Educational Programs; Required Reporting And Curriculum Approval Note.16 Requirements For Third-Party Evaluators Of Educational Programs Defect.17 Educational Programs; Mentoring Requirements; Record -Keeping Note.18 Educational Requirements For Certifying Clinicians, Practitioners, And Facilitators Open Note Defect.19 Practicum Requirements For Practitioners And Facilitators Open Note Defect.20 Requirements For Healing Centers And Other Approved Locations Note.21 Department Evaluation And Assessment Of Psilocybin Educational Programs, Healing Centers, And Other Approved Locations .22 Prohibitions And Limitations For Qualified Patients And Certificants .23 Prohibition Against Dual Ownership In Certificant And Permittee .24 Complaints To The Department .25 Informal Administrative Review Of Denied Patient Applications Note.26 Voluntary Withdrawal From Enrollment Or Relinquishment Of Certification .27 Disciplinary Actions And Appeal Process For Enrolled Patients, Patient-Applicants, Certificants, And Applicants For Certification .28 Severability
7.35.3.1

Issuing Agency

PDF p. 1

New Mexico department of health. [7.35.3.1 NMAC - N, xx/xx/2026]

7.35.3.2

Scope

PDF p. 1

This rule applies to all patients, practitioners, clinicians, facilitators, healing centers and other approved locations, and educational programs who participate or seek to participate in the New Mexico medical psilocybin program. [7.35.3.2 NMAC - N, xx/xx/2026]

7.35.3.3

Statutory Authority

PDF p. 1

This rule is promulgated pursuant to the following statutory authorities: the New Mexico Department of Health Act, Subsection E of Section 9 -7-6 NMSA 1978; and the Medical Psilocybin Act, Section 26-2D-7, NMSA 1978. [7.35.3.3 NMAC - N, xx/xx/2026]

7.35.3.4

Duration

PDF p. 1

Permanent. [7.35.3.4 NMAC - N, xx/xx/2026]

7.35.3.5

Effective Date

PDF p. 1

xx/xx, 2026, unless a later date is cited at the end of a section. [7.35.3.5 NMAC - N, xx/xx/2026]

7.35.3.6

Objective

PDF p. 1

The objective of this rule is to adopt rules governing the enrollment of qualified patients and the certification of certifying clinicians, practitioners, facilitators , educational programs, and approved locations, in accordance with the Medical Psilocybin Act at Sections 26-2D-1 through -11, NMSA 1978. [7.35.3.6 NMAC - N, xx/xx/2026]

7.35.3.7

Definitions

PDF p. 1

The definitions in 7.35.2.7 NMAC apply to this part. [7.35.3.7 NMAC - N, xx/xx/2026]

Note The definitions live in the 7.35.2 amendments. This rule defines nothing of its own. The definitions it runs on, certifying clinician, practitioner, facilitator, and the New Mexico module among them, are in the amendments to 7.35.2.7 NMAC published August 25 alongside this text. The definitions were sent to the Training and Education Committee on July 17 with the hours; the amendments carry the department's language. The program-side definitions are reproduced, verbatim and annotated, in the section directly below; the amendments PDF is in the register on the record page.
7.35.2.7

The Definitions The Rule Runs On

PDF pp. 1-4

This rule defines nothing of its own: 7.35.3.7 imports every definition from 7.35.2.7 NMAC, the producer rule's definitions section, which the amendments published August 25 rewrite. The program-side definitions are reproduced here verbatim from that amendment, in its own notation: bracketed struck text is language the amendment removes from the adopted rule, and the rest is what would stand. Every future Part of the program's rules will carry its definitions into 7.35.2.7 the same way. The full amendment, with the producer-side definitions and the changes to producer sales and transportation, is the source PDF each entry links.

Administration sessionPDF p. 1

“Administration session” means the session in which medical psilocybin is administered consumed by a qualified patient.

Administrative review committeePDF p. 1

“Administrative review committee” means an intra-department committee that reviews qualified patient application denials in accordance with department rules. The administrative review committee shall consist of the chief medical officer of the department (or that person’s designee); a deputy secretary of the department (or that person’s designee), and the chief nursing officer of the department (or that person’s designee).

Adverse health eventPDF p. 1

“Adverse health event” means a negative or detrimental medical, physical, behavioral, or psychological reaction associated with medical psilocybin services, whether expected or unexpected, that occurs during or after an administration session and that may or may not require medical or therapeutic intervention.

Approved locationPDF p. 1

“Approved location” means a location approved by the department for psilocybin administration sessions.

CertificantPDF p. 1

“Certificant” means a certifying clinician, practitioner, facilitator, healing center or other approved location, or educational program that is certified by the department to provide medical psilocybin services to qualified patients.

CertificationPDF p. 1

“Certification” means an approval issued by the department to a clinician, or a practitioner, a facilitator, a healing center or other approved location, or an educational program to provide medical psilocybin services to qualified patients participate in the medical psilocybin program.

Certifying clinicianPDF p. 1

“Certifying clinician” means a clinician who holds a state of New Mexico controlled substances number, who is certified by the department to diagnose or confirm a previous diagnosis of a qualifying condition and to evaluate the medical appropriateness of a patient enrolling in the New Mexico psilocybin program.

Open The contested scope of the screening role. The definition authorizes the certifying clinician “to diagnose or confirm a previous diagnosis of a qualifying condition,” and carries the controlled-substance number inside it. At the August 21 committee meeting the department described the role more narrowly: ensuring the medical clearance, so that the person does indeed have the diagnosis and treatment is medically appropriate, with the counseling-side judgment sitting with the treating role. The committee recommendation proposes renaming the role the medical screener and confining it to medical screening. The number requirement is analyzed on the controlled-substance number page; the August 21 exchange is on the record.
ClinicianPDF p. 1

“Clinician” means an approved health care provider licensed in New Mexico who holds a certification from the department to provide medical services to qualified patients.

Defect A definition that does not cover the certifying clinician. Both clinical roles are defined as subtypes of this term: the certifying clinician and the practitioner each “means a clinician who” meets their further conditions. But this definition reaches only a provider certified to provide “medical services”, and medical services means the three sessions, preparation, administration, and integration. The certifying clinician provides none of the three. The amendments define the broader term that would close the gap, “medical psilocybin service”, two entries below. The facilitator is defined as an individual, not a clinician.
Educational programPDF p. 2

“Educational program” means a person who is certified by the department to provide educational services for certifying clinicians, practitioners, and facilitators in accordance with this rule.

Electronic systemPDF p. 2

“Electronic system” means a department-approved online system that is used to record and report data, submit applications, and communicate with the department.

EnrollmentPDF p. 2

“Enrollment” means enrollment as a qualified patient for participation in the New Mexico medical psilocybin program.

FacilitatorPDF p. 2

“Facilitator” or “guide” means an individual who has completed training and education approved by the department to be able to work with patients and practitioners during medical psilocybin services and who has been certified by the department.

““Guide” an individual who has completed training and education approved by the department to be able to assist practitioners during the administration sessions and who has been registered with the department.

Note Struck into an alias. The adopted rule defined the guide as its own registered role, assisting practitioners. The amendment strikes that definition; guide survives only as the alternate name inside the facilitator definition above.
Healing centerPDF p. 2

“Healing center” means a person who has been issued a certification by the department to administer a site at which medical psilocybin administration sessions are conducted, to possess medical psilocybin for that purpose, and to sell or otherwise distribute psilocybin to qualified patie nts for that purpose.

Integration sessionPDF p. 2

“Integration session” means a therapeutic encounter occurring between a certified practitioner and a patient after the administration of medical psilocybin, in which the practitioner provides ongoing care to the patient.

Medical psilocybin servicePDF p. 3

“Medical psilocybin service” means any medical or therapeutic service related the medical use of psilocybin pursuant to the Medical Psilocybin Act.

Medical servicesPDF p. 3

“Medical services” means services provided to a patient in an approved setting before, during and after the ingestion of psilocybin and includes a preparation session, an administration session and an integration session.

New Mexico modulePDF p. 3

“New Mexico module” means requirements for educational study that are created by the department or its designee, that are required by applicable department rule to be completed prior to applying to be a certifying clinician, practitioner, or facilitator.

Other approved locationPDF p. 3

“Other approved location” means a site at which medical psilocybin administration sessions are to be conducted, that is not a healing center location, that is certified on a temporary basis by the department for this purpose, and whose certification is applied for by a practitioner, facilitator, or healing center.

PracticumPDF p. 3

“Practicum” means the supervised training of a student who is seeking certification as a practitioner or facilitator and requires participation in preparatory, administration, and integration sessions.

PractitionerPDF p. 3

“Practitioner” means an individual who is a licensed healthcare professional a clinician who is certified by the department to provide medical psilocybin integrative therapy, supervise guides facilitators, and who has completed department required trainings.

Note Rewritten, and the rename declined. The amendment strikes the adopted definition, “an individual who is a licensed healthcare professional,” for a certified clinician providing psilocybin integrative therapy and supervising facilitators. The committee recommendation proposes renaming the role the Licensed Provider; the published texts keep practitioner. The recommendation's position is on the recommendation page.
Preparation sessionPDF p. 3

“Preparation session” means a therapeutic encounter between a certified practitioner and a patient that occurs prior to an administration session.

Qualified patientPDF p. 4

“Qualified patient” or “patient” means a patient whose certifying clinician has judged the patient to be a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition.

Open The Act's word is clinician. The Medical Psilocybin Act defines a qualified patient as one “whose clinician has judged the patient to be a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition.” This definition substitutes the narrower defined term, whose certifying clinician has judged, which places the statutory judgment of medical appropriateness in the one role that carries the controlled-substance number inside its definition. The Act's own definition of clinician names no license type and no controlled-substance number; the requirement is analyzed on the controlled-substance number page.
Qualifying conditionPDF p. 4

“Qualifying condition” includes: (a) major treatment-resistant depression; (b) posttraumatic stress disorder; (c) substance use disorders; (d) end-of-life care; and (e) other conditions approved by the department;

Note Where the conditions bind the curriculum. End-of-life care, post-traumatic stress disorder, and substance use disorders are three of the four qualifying conditions, and none is a named topic in the didactic list at 7.35.3.18 (C); the list's nearest counterpart is “Education on the qualifying conditions and appropriate treatment practices.”
Registrant of another approved locationPDF p. 4

“Registrant of another approved location” means a practitioner, facilitator, or healing center who applies for and receives certification for an “other approved location”.

7.35.3.8

Patient Enrollment Application Process

PDF p. 1

A completed patient application shall be submitted by a patient and the patient’s certifying clinician using the electronic system designated by the department, in accordance with the following:

A. Patient submittal requirements: An applicant for enrollment as a qualified patient in the medical psilocybin program shall submit the following information to the department: (1) Applicant’s legal name, address, telephone number, and e-mail address; (2) Applicant’s date of birth; (3) Name of the applicant’s certifying clinician; (4) A legible copy of the patient’s driver’s license or comparable photo identification card; (5) The applicant’s signature and date; (6) A signed consent for release of medical information related to the patient’s qualifying medical condition, on a form provided by the medical psilocybin program; (7) Completed affirmation form, which shall include but not be limited to attestations that: (a) The applicant has a qualifying diagnosis; (b) The applicant provided information to the certifying clinician that was, to the best of the applicant’s knowledge, true and correct; (c) The applicant has discussed with their certifying clinician the risks and benefits of medical psilocybin usage, and that the applicant understands those risks; and (8) Such additional information and documentation as the department may reasonably require.

B. Certifying clinician submittal requirements: A certifying clinician shall submit the following information to the department in support of a patient’s application for enrollment in the medical psilocybin program: (1) Name of applicant for patient enrollment; (2) Name, address, telephone number, and e-mail address of the certifying clinician; (3) Clinical licensure of the certifying clinician, including controlled substance number; (4) The patient’s qualifying diagnosis, the date of diagnosis or date of confirmation of the diagnosis; (5) Documentation of diagnosis of qualifying condition by a certifying clinician; (6) If the in-person exam was conducted by another clinician: the name and contact information for the clinician who performed the exam; (7) Information required for patient participation in the Equity and Access Fund (as applicable); (8) Completed affirmation forms, which shall include but not be limited to attestations that: (a) The applicant has a qualifying diagnosis; (b) The certifying clinician has discussed with the applicant the risks and benefits of medical psilocybin usage; (c) The certifying clinician has evaluated the medical appropriateness of the patient’s proposed enrollment in the New Mexico psilocybin program, and that, in the clinician’s professional opinion, the potential health benefits of the medical use of psilocybin would likely outweigh health risks for the patient; and (i) the certifying clinician has conducted an in-person examination of the patient within the previous six months; (ii) the certifying clinician has conducted a patient evaluation via telemedicine and has reviewed the medical records pertaining to the diagnosis of a qualifying condition and has confirmed the medical records of the diagnosis are from a clinician who has conducted an in- person examination of the patient within the previous six months; or (iii) the certifying clinician has conducted a patient evaluation via telemedicine and has had a formal consultation with a clinician who has conducted an in-person exam with the patient within the previous six months; and (9) Such additional information and documentation as the department may reasonably require.

C. Once the department has received a completed application, it will review the application and render a decision within 30 calendar days. (1) The department will notify the patient of the approval or denial of the application through the electronic system designated by the department. (2) The department may verify information contained in an application by reference to information submitted by a certifying clinician, and by otherwise contacting a certifying clinician to obtain information and review medical records.

D. A person whose application for patient enrollment is denied for failure to complete an application or failure to meet a submittal requirement of this rule may request a record review to be conducted by the department, in accordance with this rule.

E. A qualified patient’s enrollment in the medical psilocybin program shall expire two years after the initial date of enrollment. If additional treatment is needed, a qualified patient may re-enroll if their enrollment has expired. [7.35.3.8 NMAC - N, xx/xx/2026]

7.35.3.9

Certifying Clinician, Practitioner, And Facilitator Application Process

PDF p. 2

An individual may apply for certification as a certifying clinician, practitioner, or facilitator in the medical psilocybin program in accordance with this rule. The applicant shall submit a completed application packet through the electronic system designated by the department.

A. Approval and denial; certification period: (1) Once the department has received a completed application, it will review the application and render a decision within 30 calendar days. (2) The department will notify the applicant of the approval or denial of the application through the electronic system designated by the department. (3) If the application is approved, the certification shall be effective on the date of notice and shall be valid for two years. (4) If the department denies an application, the department shall provide notice of the denial within 30 calendar days in accordance with this rule. (5) If the application is denied, the applicant may re-apply within six months. (6) An applicant who is denied a second time may not re-apply for six months from the denial. (7) An applicant whose application is denied may appeal the denial in accordance with this rule.

B. Renewal of certification; submittal deadline: Applicants for renewal of certification shall submit a completed renewal application packet through the electronic system designated by the department no more than 60 calendar days and no less than 30 calendar days prior to the expiration of their current certification.

C. General application requirements: An applicant for certification as a certifying clinician, practitioner, or facilitator shall submit the following as part of their completed application packet , using the electronic system designated by the department: (1) Applicant’s legal name, address, telephone number, and e-mail address; (2) A legible copy of the applicant’s driver’s license or comparable photo identification card; (3) Documentation that the applicant has completed the applicable educational requirements and practicum requirements; (4) Documentation of satisfaction of continuing education requirements (if applying for renewal); (5) Completed affirmation and consent forms: (a) Consent to publication of contact information (name, phone number, e -mail address); (b) Affirmation that all of the information submitted is true and accurate; and (c) Attestation that the applicant is not registered in any jurisdiction as a sex offender; (6) The applicant’s signature and date of application submittal.

D. Certifying clinician application requirements: An applicant for certification as a certifying clinician shall additionally submit the following, using the electronic system designated by the department: (1) Documentation of current professional license to practice in New Mexico and diagnose the qualifying conditions (e.g., MD, NP); (2) NM controlled substance number; (4) Documentation of HIPAA certification completed within the preceding two years; (5) Completed W-9 form; and (6) Such additional information and documentation as the department may reasonably require.

E. Practitioner application requirements: An applicant for certification as a practitioner shall additionally submit the following, using the electronic system designated by the department: (1) Documentation of current professional license to practice therapy, counseling, or behavioral services in New Mexico (e.g., PSY, LSW, LCSW); (2) Documentation of completion of the department-approved practicum requirements; (3) Documentation of current: (a) Basic life support (BLS) certification; (b) Both cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) certification; or (c) Licensure as a New Mexico emergency medical technician (e.g., EMT-basic, EMT-intermediate, EMT-paramedic); (4) Documentation of HIPAA certification completed within the preceding two years; (5) Completed W-9 form; and (6) Such additional information and documentation as the department may reasonably require.

F. Facilitator application requirements: An applicant for certification as a facilitator shall additionally submit the following, using the electronic system designated by the department: (1) Documentation of completion of the department-approved practicum requirements; (2) Documentation of current: (a) Basic life support (BLS) certification; (b) Both cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) certification; or (c) Licensure as a New Mexico emergency medical technician (e.g., EMT-basic, EMT-intermediate, EMT-paramedic); (3) Documentation of HIPAA certification completed within the preceding two years; (4) Completed W-9 form; and (5) Such additional information and documentation as the department may reasonably require. [7.35.3.9 NMAC - N, xx/xx/2026]

Settled Controlled-substance number, kept. The requirement that a certifying clinician hold a New Mexico controlled-substance number was contested through June and July and kept by the department on July 17. It stands in this section, and the amended definition of certifying clinician in 7.35.2.7 now carries the number inside it. The full account is on the controlled-substance number page.
7.35.3.10

Application Process For Certification As A Certifying Clinician, Practitioner, Or Facilitator Based On Educational Programs From Other Jurisdictions

PDF p. 4

A. List of department-approved psilocybin educational programs from other jurisdictions: (1) The department shall maintain a list of psilocybin educational programs from other jurisdictions that have been identified by the department as being equivalent to the didactic educational requirements applicable for New Mexico certification, and that may be utilized as a basis for certification pursuant to this rule section. (2) Educational programs shall be added to the list when an application for certification as a certifying clinician, practitioner, or facilitator is submitted and approved based on the applicant’s completion of the out-of-state educational program. (3) Such educational programs shall include both government-approved psilocybin educational programs from other jurisdictions (including but not limited to psilocybin educational programs approved by the states of Oregon and Colorado as of December 31, 2027), and psilocybin educational programs developed in collaboration with higher institutes of education or government -approved psychedelic research studies. (4) Educational programs that are added to the department list of approved psilocybin educational programs from other jurisdictions shall remain on the list for two years, except that: (a) Educational programs that have been added to the department approved list will be removed if they lose certification, approval, or licensure from their issuing jurisdiction; and (b) An educational program from the department list of approved psilocybin educational programs from other jurisdictions may be removed if the department determines that the didactic requirements of the educational program are no longer equivalent to those applicable for New Mexico certification. (5) Consistent with this rule, educational programs that are included on the list of approved educational programs from other jurisdictions do not hold certification under this rule, and shall not be entitled to an administrative appeal in the event that the educational program is removed from the list.

B. Applications for certification based on a psilocybin educational program from another jurisdiction: An individual may apply for certification to be either a certifying clinician, practitioner, or facilitator in New Mexico on the basis of having completed a psilocybin educational program from another jurisdiction. A n applicant for such certification shall submit the following, using the electronic system designated by the department: (1) All of the information and documentation required for a certifying clinician, practitioner, or facilitator under the preceding section of this rule; (2) Documentation of either: (a) Completion of a government approved psilocybin educational program from another jurisdiction, which shall include: (i) Documentation that the curriculum of the educational program is equivalent to the didactic educational requirements applicable for New Mexico certification ; and (ii) For all applications received on or after January 1, 2028, documentation of a third-party evaluation of the curriculum demonstrating such equivalency; (b) Completion of a psilocybin educational program from another jurisdiction that is developed in collaboration with higher education institutions or government-approved psychedelic research studies, which shall include: (i) Documentation that the curriculum of the educational program is equivalent to the didactic educational requirements applicable for New Mexico certification , and (ii) For all applications received on or after January 1, 2028, documentation of a third-party evaluation of the curriculum demonstrating such equivalency; or (c) Completion of an educational program that is currently included on the list of department-approved psilocybin educational programs from other jurisdictions. (3) Documentation of completion of the New Mexico required educational module; and (4) Documentation of completion of practicum or practice with the minimum number of patients and hours as required by this rule.

C. Application approval and denial; certification period: If the application is approved, the certification shall be effective on the date of notice and shall be valid for two years. If the department denies an application, the department shall provide notice of the denial in accordance with this rule. If the application is denied, the applicant may re-apply within six months. An applicant who is denied a second time may not re-apply for six months from the denial. An applicant whose application is denied may appeal the denial in accordance with this rule.

D. Waiver of practicum requirements: (1) An applicant for certification as a practitioner or facilitator on the basis of an educational program from another jurisdiction and whose application is received by the department by December 31, 2027, shall not be required to complete the full practicum hours required by this rule, but shall demonstrate completion of at least 40 hours of contact time with a minimum of two separate individual sessions and two separate group sessions for preparation, administration, and integrative therapy with psilocybin treatment. (2) The department may otherwise waive, temporarily suspend, or reduce the practicum requirements for individuals applying on the basis of having completed a psilocybin educational program from another jurisdiction, in order to facilitate the certifying of individuals trained by other governmental approved programs to build the initial infrastructure of the program. [7.35.3.10 NMAC - N, xx/xx/2026]

Settled Reciprocity deadlines, settled July 9. Both reciprocity waiver deadlines were extended to December 31, 2027 at the July 9 board meeting, resolved without objection. The board chair described December 31 as a legislative backstop. Source: July 9 meeting transcript.
7.35.3.11

Application Process For Healing Centers And Other Approved Locations

PDF p. 5

A. Applications for healing centers: An applicant seeking certification as a healing center shall submit a complete application through the electronic system designated by the department. A complete application shall include, at minimum, the following: (1) Applicant’s legal name, address, telephone number, and e-mail address; (2) Names and contact information of primary contact person(s) and any affiliated practitioners or facilitators; (3) An organizational chart depicting the applicant’s governance and operational structure; (4) Proof of registration with the New Mexico secretary of state; (5) Proof of registration with the New Mexico taxation and revenue department; (6) Copies of any required business licenses issued by applicable New Mexico cities or counties; (7) A certificate of occupancy for each location in New Mexico where the program will conduct operations; (8) Proof of ownership of any property on which medical psilocybin administration sessions will be conducted, or a signed, written statement from the owner of such property acknowledging that the owner understands that persons will be participating in the medical psilocybin program on the premises, and what those persons are authorized to do within the terms of their certification; (9) Proof of compliance with applicable laws and regulations governing accessibility for individuals with disabilities; (10) A list of all owners or members of the board of directors, including corresponding contact information; (11) Primary program contact information, including name, physical address, telephone number, and e-mail address; (12) Record retention plan; (13) Plan for maintaining confidentiality of patient information; (14) A safety and emergency response plan appropriate to the location’s operational settings, to include adverse health event response and reporting; (15) A written outline of the location’s complaint and grievance procedures available to patients; (16) Plan for secured storage for medical psilocybin; (17) Plans for wastage of any unused medical psilocybin; (18) Plan demonstrating how patient confidentiality will be maintained within the healing center; (19) Plan for transparency and disclosure of fees for patients; (20) Proof that the location has a functioning communication device which can reliably reach emergency medical services; (21) For a location that intends to conduct administration sessions in an outdoor or natural environment: (a) A detailed description of the outdoor administration area, including identification of safe entrances and exits, and verification that the area is free from hazards; (b) An emergency safety and response plan; and (c) Proof that emergency medical services can reliably be contacted from, and respond to, the location at which medical psilocybin administration sessions will occur . (22) A list of all other employees of the organization, including their legal names; (23) Completed affirmation and consent forms: (a) Consent to publication of contact information (name, phone number, e-mail address, website), if certified; (b) Affirmation that all of the information submitted is true and accurate; and (c) Attestation that no persons associated with the applicant are registered in any jurisdiction as a sex offender; (24) Signature of authorized representative and date of application submittal; and (25) Such additional information and documentation as the department may reasonably require.

B. Applications for other approved locations: A practitioner or facilitator may apply for temporary department certification of an “other approved location”. Other approved locations are physical locations at which medical psilocybin is intended to be consumed, that are not locations of healing centers. Such locations may be certified if a qualified patient is unable to be physically transported to a healing center , for other reasons of medical necessity, for purposes of improving patient access in rural and frontier counties, or to enable treatment to occur in a natural environment setting. Such locations may include a patient’s residence, or another temporary location. An applicant who seeks certification of such a location shall submit a complete application using the electronic system designated by the department. A complete application shall include, at minimum, the following: (1) Address and description of the location to be utilized; (2) Plan for secure transportation and safe storage for medication; (3) Plans for wastage of any unused medicine; (4) A safety and emergency response plan; (5) Proof that the location has a functioning communication device which can reliably reach emergency medical services; (6) Plan for safe storage of any firearms on the premises during and after treatment sessions; (7) Plan demonstrating how patient confidentiality will be maintained; (8) A statement regarding the appropriateness of the location for treatment sessions; (9) Proof of ownership by the qualified patient or attending practitioner or facilitator of any property on which medical psilocybin administration sessions will be conducted, or a signed, written statement from the owner of such property acknowledging that the owner understands that persons will be participating in the medical psilocybin program on the premises, and what those persons are authorized to do within the terms of their certification; (10) For outdoor or natural environments: (a) A detailed description of the administration area, including identification of safe entrances and exits, and verification that the area is free from hazards; (b) An emergency safety and response plan; and (c) Proof that emergency medical services can reliably be contacted from, and respond to, the location at which medical psilocybin administration sessions will occur; (11) Affirmation that all of the information submitted is true and accurate; (12) Signature of authorized representative and date of application submittal; and (13) Such additional information and documentation as the department may reasonably require.

C. Application for renewal of certification for healing centers: An applicant seeking renewal of certification as a healing center shall submit a complete renewal application packet through the department - approved electronic system no more than 60 calendar days and no less than 30 calendar days prior to the certification’s expiration date.

D. Certification period; approval and denial: Certification of a healing center shall be effective on the date of department issuance and shall be valid for two years. Certification of other approved locations shall be effective on the date of department issuance and shall be valid for 90 calendar days. If the department denies an application for a healing center or other approved location, the department shall provide notice of the denial within 30 calendar days in accordance with this rule. If the application is denied, the applicant may re-apply within six months. An applicant who is denied a second time may not re-apply for six months from the denial. An applicant whose application is denied may appeal the denial in accordance with this rule. [7.35.3.11 NMAC, xx/xx/2026]

Open The owner statement at a patient's home. An other approved location may be a patient's residence, and the pathway exists in the first instance for a patient who cannot be physically transported to a healing center. Paragraph (9) of Subsection B requires proof of ownership of the property by the patient, practitioner, or facilitator, or “a signed, written statement from the owner of such property acknowledging that the owner understands that persons will be participating in the medical psilocybin program on the premises”. A patient who rents cannot receive treatment at home unless the landlord signs that statement, which discloses the household's program participation to a party with no role in the patient's care; Paragraph (7) of the same subsection requires a plan for maintaining patient confidentiality at the same location. The at-home pathway exists in the first instance for patients who cannot be transported to a healing center, end-of-life patients among them. Landlord approval and patient privacy were raised at the August 21 committee meeting, from the chat and read into the record by the chair, who called it a sticky subject to be discussed further; the question had been raised at an earlier end-of-life meeting. The exchange is on the record. Public comment continues through the October 2 hearing.
7.35.3.12

Application Process For Psilocybin Educational Programs

PDF p. 7

A. Application requirements: An applicant seeking certification as a psilocybin educational program shall submit a complete application through the electronic system designated by the department. A complete application shall include, at minimum, the following: (1) An organizational chart depicting the applicant’s governance and operational structure ; (2) Proof of registration with the New Mexico secretary of state; (3) Proof of registration with the New Mexico taxation and revenue department; (4) Copies of any required business licenses issued by applicable New Mexico cities or counties; (5) A certificate of occupancy for each location in New Mexico where the program will conduct operations; (6) Proof of compliance with applicable laws and regulations governing accessibility for individuals with disabilities; (7) A list of all owners or members of the board of directors, including corresponding contact information; (8) Primary program contact information, including name, physical address, telephone number, and email address; (9) A record retention plan; (10) A safety and emergency response plan appropriate to the program’s operational settings; (11) A written outline of the program’s complaint and grievance procedures available to students; (12) A signed consent authorizing the department to publicly list the program’s contact information and website, if certification is granted; (13) A list of all instructors, accompanied by curricula vitae or resumes demonstrating collective expertise sufficient to meet all required curriculum areas; (14) A copy of the curriculum to be utilized by the program, including a brief description demonstrating how the curriculum satisfies the department’s curriculum requirements; (15) Copies of all course syllabi and a web address at which the program will publicly maintain updated syllabi for prospective students; (16) A plan describing how the program will ensure transparency in the disclosure of all student fees; (17) A plan demonstrating how the program will ensure that enrolled students complete all required components and graduate within two years of enrollment; (18) A signed consent authorizing the department to publicly list the curriculum and syllabi submitted with the application, if approval is granted; (19) A third‑party evaluation report that is conducted by a qualified third-party evaluation team in accordance with this rule, and that complies with the requirements of this section; (20) Proof of established arrangements with healing centers or other department‑approved locations for student practicum placements; (21) Documentation demonstrating that, no later than December 31, 2027, the program will employ at least two faculty members who hold current practitioner or facilitator certificates issued by the department; (23) A list of all other employees of the organization, including their legal names; and (24) Such additional information and documentation as the department may reasonably require.

B. Third-party evaluation reports: Applications for certification as an education program shall include a third-party evaluation report, generated in accordance with this rule, that assesses the organization and curriculum of the educational program and that demonstrates that the educational program meets requirements for medical psilocybin educational programs in New Mexico. (1) Applications for certification as an education program that are submitted on or before December 31, 2027 may be approved without an accompanying third-party evaluation report, provided that the applicant submits the third-party evaluation by December 31, 2027. If the third-party evaluation is not submitted, the certification will be rescinded. (2) Applications for certification as an education program that are submitted after December 31, 2027 shall include the third-party evaluation.

C. Application for renewal of educational program certification: An applicant seeking renewal of its psilocybin educational program certification shall submit a complete renewal application packet through the department-approved electronic system no more than 60 calendar days and no less than 30 calendar days prior to the certification expiration date.

D. Approval and denial; certification period: If the application is approved, the certification shall be effective on the date of notice and shall be valid for two years. If the department denies an application, the department shall provide notice of the denial in accordance with this rule. If the application is denied, the applicant may re-apply within six months. An applicant who is denied a second time may not re-apply for six months from the denial. An applicant whose application is denied may appeal the denial in accordance with this rule. [7.35.3.12 NMAC - N, xx/xx/2026]

7.35.3.13

Requirements And Prohibitions For Certifying Clinicians, Practitioners, And Facilitators

PDF p. 8

A. Certifying clinicians; actual clinician-patient relationship required; telemedicine: (1) In order to certify a patient, a certifying clinician must have an actual clinician -patient relationship with the patient. The certifying clinician shall conduct an in-person physical evaluation and medical clearance of the applicant or qualified patient prior to issuing a certification; or (2) A certifying clinician may issue a patient certification on the basis of an evaluation conducted via telemedicine if one of the following conditions applies: (i) the certifying clinician has conducted an in-person examination of the patient within the previous six months; (ii) the certifying clinician has conducted a patient evaluation via telemedicine and has reviewed the medical records pertaining to the diagnosis of a qualifying condition and has confirmed the medical records of the diagnosis are from a clinician who has cond ucted an in-person examination of the patient within the previous six months; or (iii) the certifying clinician has conducted a patient evaluation via telemedicine and has had a formal consultation with a clinician who has conducted an in-person exam with the patient within the previous six months.

B. Facilitators; scope of work: A facilitator is authorized to work alongside a practitioner during medical psilocybin services. A facilitator works under the direct supervision of a practitioner, and provides peer support to qualified patients, as well as logistical and administrative support to the practitioner and to the healing center. A facilitator shall not perform any patient care outside this scope, unless another license held by the facilitator permits it.

C. Practitioners and facilitators; submittal of patient treatment information to department: Practitioners and facilitators shall maintain the following information and submit such information to the department using the electronic system designated by the department: (1) Dates and types of services provided to patients for evaluation and preparation sessions; (2) Information concerning the administration of medical psilocybin to the patient, including but not limited to: (a) Dates of administration of medical psilocybin products, and healing centers and other approved locations where medical psilocybin was administered to the patient; (b) Unique identification numbers of medical psilocybin products administered; (c) Dosage of medical psilocybin products administered; (d) Dates of initial integrative sessions; and (e) Any adverse health events; and (3) Such additional information and documentation as the department may reasonably require.

D. Practitioners and facilitators; psilocybin product information; notification to patients of failed test results: (1) A practitioner or facilitator who administers a psilocybin product to a qualified patient shall, upon request, make reasonable efforts to provide a translation of the psilocybin product information document in languages other than English and in an accessible format. (2) A practitioner or facilitator who administers to a patient a psilocybin product that is determined by a producer to have come from a psilocybin lot that failed required testing shall timely forward the producer’s notification of the failed test to the qualified patient who consumed the product.

E. Certifying clinicians, practitioners, and facilitators; prohibition against certifying or treating certain relatives: A certifying clinician, practitioner, or facilitator shall not certify or treat a patient who is related to the certifying clinician, practitioner, or facilitator within the second degree of consanguinity or the first degree of affinity. This includes a spouse, child, stepchild, parent, stepparent, sibling, grandparent, mother -in-law, father-in- law, son-in law, or daughter-in-law.

F. Certifying clinicians, practitioners, and facilitators; prohibition against intoxicants: A certifying clinician, practitioner, or facilitator shall not consume or otherwise be under the influence of psilocybin or any other intoxicant when providing services to a patient.

G. Record access: Certifying clinicians, practitioners, and facilitators shall timely provide the department access to records upon the department’s request. [7.35.3.13 NMAC, xx/xx/2026]

Note New in this text. Two provisions appear here for the first time in the August 25 text: a certifying clinician, practitioner, or facilitator shall not consume or be under the influence of psilocybin or any other intoxicant when providing services to a patient, Subsection F, and certifying clinicians, practitioners, and facilitators must provide the department access to records on request, Subsection G.
7.35.3.14

Authorized Possession, Purchase, Or Sale Of Medical Psilocybin By Practitioners, Facilitators, Healing Center Owners And Employees; Chain Of Custody

PDF p. 9

Certification of a practitioner, facilitator, or healing center shall enable practitioners, facilitators, and owners and employees of healing centers to do the following, in accordance with medical psilocybin program rules: (A) Practitioners: Practitioners may purchase and possess medical psilocybin products obtained from permitted producers, and may sell or otherwise provide medical psilocybin products to qualified patients during administration sessions conducted at a healing center location or other approved location. A practitioner may only sell or otherwise provide psilocybin products that are obtained from permitted producers. (B) Facilitators: Facilitators may possess medical psilocybin products, for the purpose of providing those products to qualified patients in administration sessions conducted at healing centers and other approved locations. (C) Healing centers: Owners and employees of healing centers who are registered with the department may purchase medical psilocybin products from permitted producers, may possess medical psilocybin products, and may sell or otherwise administer those products to qualified patients in administration sessions conducted at the healing center or other approved locations, provided that such individuals are also designated to engage in each activity by the healing center. A healing center may only sell or otherwise provide psilocybin products that are obtained from permitted producers. (D) Chain of custody; documentation: A practitioner, facilitator, or healing center owner or employee who obtains or transfers medical psilocybin shall generate and submit a chain of custody form through the electronic system designated by the department, unless the chain of custody form is otherwise generated and submitted by a producer, in which case the person who receives the psilocybin shall verify that the psilocybin is accurately reflected in the system. A practitioner, facilitator, or healing center owner or employee who obtains or transports psilocybin shall be prepared to show proper identification, including an employee badge, driver’s license, vehicle registration and proof of insurance, and the appropriate chain of custody form to law enforcement and the department when requested. [7.35.3.14 NMAC, xx/xx/2026]

Defect Students are not authorized here. The practicum in 7.35.3.19 requires students to conduct administration sessions, and 7.35.3.20 lets students count toward staffing, but this section authorizes no student to possess or administer psilocybin. Stated in the July 25 concerns inventory, finding B1, and analyzed at 7.35.3.14 on What a practicum change touches.
Defect A registration this rule does not create. Subsection C conditions healing-center owner and employee authorization on registration with the department, and the rule creates no such registration. Finding B5, analyzed at the missing healing-center registration on What a practicum change touches.
Note New in this text: chain of custody. Paragraph D, new in the August 25 text, requires a practitioner, facilitator, or healing center owner or employee who obtains or transfers medical psilocybin to generate or verify a chain of custody form, and to carry identification and the form when transporting. It pairs with the amended transportation rules in 7.35.2.24, published the same day.
7.35.3.15

Psilocybin Educational Programs; Required Reporting And Curriculum Approval

PDF p. 9

A. Review and approval of psilocybin educational program curriculum: The department shall review and evaluate the proposed curriculum, both for an initial application for psilocybin educational program certification and subsequent modifications to an approved curriculum, and shall determine whether to approve or deny the curriculum. The department may deny a proposed curriculum if: (1) It does not meet the overall minimum hour requirements; (2) It does not meet the specific requirements for each module; (3) If the materials present incorrect or outdated information, or information that poses a substantial threat to public health or safety; (4) If the proposed curriculum does not clearly outline how the required topics will be covered in sufficient depth for students to understand them; or (5) If the department otherwise determines that the curriculum fails to meet the educational objectives of this rule.

B. Required reporting of updates: A department-certified psilocybin educational program shall notify the department, through the electronic system designated by the department, of any of the following changes, and shall not implement the change until written approval is issued by the department: (1) Any revision to the program’s curriculum; revised curricula shall be submitted to the department for review and may not be implemented until the department grants approval; (2) Any change in ownership, including changes in controlling interest or organizational structure; (3) Any change in physical locations utilized for instruction or educational activities ; (4) Any modification, termination, or addition of practicum site agreements; and (5) Any change in instructional or other staff, including submission of curricula vitae or resumes for all newly added instructors.

C. Psilocybin educational program curriculum approval process: Applicants shall submit a complete application packet for curriculum approval through the electronic system designated by the d epartment. The department shall notify the applicant within 60 calendar days, through the department-approved electronic system, of whether the application is approved or denied. If approved, the approval shall take effect on the date of the notice and shall remain valid for two years. If denied, the department shall issue notice through the department- approved electronic system stating the basis for the denial. An applicant whose application has been denied may resubmit a corrected application within six months. No applicant may resubmit an application more than two times following an initial denial. An applicant may appeal a denial in accordance with the appeals process established in this rule. [7.35.3.15 NMAC - N, xx/xx/2026]

Note New in this text. Subsection A, new in the August 25 text, puts every educational program curriculum through department review and approval, initial applications and later modifications alike, with five stated grounds for denial.
7.35.3.16

Requirements For Third-Party Evaluators Of Educational Programs

PDF p. 10

A. General requirements: A psilocybin educational program shall engage a qualified third-party evaluation team to conduct the evaluations required under this rule. The evaluation team shall consist of no fewer than three individuals who collectively meet all competency requirements set forth in this section.

B. Minimum qualifications: Each evaluator shall possess at least three years of professional experience in one or more of the following fields, and the evaluation team as a whole shall demonstrate expertise covering all listed domains: (1) Psilocybin therapy practice, supported by a master’s or doctoral degree in counseling, therapy, social work, public health, behavioral health, or a closely related field; (2) Medical and research practice, supported by a master’s or doctoral degree in medicine, pharmacy, nursing, or another related clinical or scientific field; and (3) Educational curriculum development and evaluation, supported by a master’s or doctoral degree in education, educational psychology, or a closely related field.

C. Conflict of -interest prohibitions: (1) All evaluators shall be free from actual or perceived conflicts of interest regarding the organization or curriculum under review. (2) The following conflicts, at minimum, shall disqualify an individual from serving as an evaluator: (a) Participation in the design, development, or teaching of the curriculum being evaluated; or (b) Holding a financial interest in, receiving compensation from, or serving in any governance or advisory capacity with the program or organization being evaluated.

D. Confidentiality and impartiality: Prior to initiating evaluation activities, each evaluator shall sign a confidentiality and impartiality agreement affirming their obligation to maintain confidentiality, avoid bias, and act independently in carrying out evaluation responsibilities.

E. Evaluation report requirements: The evaluation team shall prepare a written evaluation report and shall submit the report simultaneously to both the psilocybin educational program and the department. The report shall include, at a minimum: (1) A description of each evaluator’s professional qualifications and experience relevant to the required evaluation domains; (2) Copies of all signed conflict of interest, confidentiality, and impartiality agreements; (3) An assessment of the reliability, validity, and fidelity of implementation of the curriculum; (4) An assessment of the reliability, validity, and fidelity of implementation of student competency evaluations, including examinations, assessments, and instructor observational feedback; (5) An assessment of student feedback processes and a summary of the feedback; (6) Recommendations for corrective actions or improvements, where applicable; (7) Performance evaluations of all faculty members participating in the program; and (8) A review and evaluation of any reported student grievances related to program instruction, curriculum implementation, or student assessment processes. [7.35.3.16 NMAC - N, xx/xx/2026]

Defect Paid evaluators are disqualified by the conflict rule. The program must engage and pay the third-party evaluation team, and the section's own conflict rule disqualifies paid evaluators. Finding B3.
7.35.3.17

Educational Programs; Mentoring Requirements; Record -Keeping

PDF p. 11

A. All educational programs shall provide each practitioner and facilitator student with a minimum of 10 hours of mentoring sessions after graduation and after practicum hours are completed. The purpose of the mentoring sessions is to allow new graduates to consult with the educational program faculty regarding cases, patients, situations, and how they handle them. These mentoring sessions may not have additional associated charges beyond the cost of the educational program itself. The 10 hours are valid for up to 12 months after practicum hours are completed. If students request more than 10 hours of mentoring sessions, this will be at the purview of the educational program and may have an additional associated cost.

B. Educational programs shall offer an option for a student to complete the evaluation for each educational module (not including the New Mexico module) without attending the lessons or classes for the module. The cost to complete the evaluation for each module shall not be greater than one -fourth of the normal price of each of the educational modules. If the student receives a passing grade for a module evaluation, they will have been considered to have completed the module; and if a student does not receive a passing grade for a module evaluation, they will not have completed the module. The educational program may at its discretion allow students to re-take the evaluation without attending the lessons or classes for the modules. Students who utilize this option shall complete all other requirements for the educational program, including the New Mexico m odule, certifications, simulated patient, and practicum requirements to graduate from the educational program.

C. Educational programs shall maintain the following records for a minimum of five years, and as required by applicable law: (1) All course syllabi; and (2) Enrollment records, including but not limited to the: (a) Name of each student; (b) Date of start and completion for each student; (c) Examination results and transcripts for each student; (d) Dates, locations, and number of patients seen during each of the practicum sessions; and (e) Names of facilitators supervised by practitioner students during practicum.

D. Educational programs shall upload the completion certificate into the electronic system designated by the department.

E. Educational programs shall provide current and former students their records upon request.

F. Educational programs shall collect feedback from students within 30 calendar days of the completion of each module, which shall include, at a minimum, ratings and qualitative responses regarding the quality, quantity, and satisfaction of the students with the course pedagogy, materials, presentations, lectures, assignments, evaluations, and course content.

G. Educational programs shall provide records required to be maintained under this rule to the department upon request. [7.35.3.17 NMAC - N, xx/xx/2026]

Note New in this text. Educational programs must collect structured student feedback within 30 calendar days of each module's completion, Subsection F, new in the August 25 text.
7.35.3.18

Educational Requirements For Certifying Clinicians, Practitioners, And Facilitators

PDF p. 11

A. Requirements for certifying clinician, practitioner, and facilitator certification: All certifying clinicians, practitioners, and facilitators who provide medical psilocybin services, including all such providers who are certified by the department on the basis of having completed an educational program from another jurisdiction, shall complete a New Mexico educational module created or approved by the department prior to applying for certification, which shall include at a minimum: (1) Education on the New Mexico Medical Psilocybin Act; (2) An overview of the use of psilocybin in a medical and therapeutic model in New Mexico; (3) Education on the social, cultural and historical aspects of psilocybin use, including traditional use by Native American and other populations in New Mexico; (4) Spiritual, existential, religious, and theological (SERT) aspects of psilocybin therapy; and (5) Evaluation to demonstrate competency in the above areas.

B. Requirements for initial certifying clinician certification: All certifying clinicians shall complete a certifying clinician module consisting of a minimum of eight didactic hours prior to applying for certification, which shall include: (1) Psilocybin action, interactions, and pharmacology; (2) Overview of certifying clinician responsibilities; (3) 42 CFR part 2; (4) Education on diagnosis of qualifying conditions; (5) Determining medical clearance for psilocybin therapy; (6) Psychedelic emergencies/urgencies and medical monitoring; (7) Research and data collection requirements; and (8) Evaluation to demonstrate competency in the above areas.

C. Requirements for initial practitioner and facilitator certification: All practitioners and facilitators shall complete a psilocybin therapy module consisting of a minimum of 65 didactic hours with at least one third of the didactic hours conducted in person, and 10 hours of simulated patient experience, prior to applying for certification. The therapy module shall include the following: (1) The didactic portion, which shall address the following topics at a minimum: (a) Overview of practitioner/facilitator responsibilities including how to work as part of a care team; (b) 42 CFR part 2; (c) Trauma-informed Care (d) Psychedelic emergencies, urgencies, complications, and medical monitoring; (e) Safety, risk mitigation, and harm reduction practices; (f) Psilocybin actions and effects on the body, interactions, and pharmacology; (g) Drug interactions and pharmacology; (h) Set and setting; (i) Ethics in therapeutic settings; (j) Legal considerations; (k) Cultural competencies; (l) Traditional and ceremonial practices and considerations; (m) Equity and access; (n) Patient-centered approaches and care; (o) Education on the qualifying conditions and appropriate treatment practices; (p) Preparation and integration sessions; (q) Administration session; (r) Dosing; (s) Psychedelic de-escalation techniques; (t) Non-ordinary states of consciousness; (u) Self-care; (v) Research and data collection requirements; (w) Evidence-informed practices and research updates; (x) Informed consent; (y) Touch and somatic awareness; (z) Continuity of care and creating care plans; and (aa) Evaluation to demonstrate competency in the above areas. (2) An in-person simulated patient experience of no less than five hours,; and an additional simulated patient experience of no less than five hours, which may be in- person, virtual, either synchronous or asynchronous, and which shall include evaluation of the student to demonstrate competency. These shall include evaluation of the student to demonstrate competency.

D. Additional requirements for initial facilitator certification: All facilitators shall complete a facilitator-specific training module consisting of a minimum of five didactic hours, prior to applying for certification, which shall include: (1) Peer facilitation ethics; (2) How to work as part of a care team; (3) What it means to be present with a patient; (4) For informational purposes: basic concepts of psychotherapy; and (5) Evaluation to demonstrate competency in the above areas.

E. Additional requirements for initial practitioner certification: All practitioners shall complete a module on psychedelic and psilocybin therapeutic approaches consisting of a minimum of five didactic hours, prior to applying for certification, which shall include: (1) additional education of psilocybin specific therapeutic modalities and non-ordinary states of consciousness; (2) education on how to work as part of a care team; and (3) evaluation to demonstrate competency in the above areas.

F. Practitioner and facilitator trainings: All practitioners and facilitators shall also complete and maintain proof of current certification prior to applying for medical psilocybin certification in: (1) Documentation of current: (a) Basic life support (BLS); (b) Both cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) certification; or (c) Licensure as a New Mexico emergency medical technician (e.g., EMT-basic, EMT-intermediate, EMT-paramedic); and (2) Documentation of HIPAA certification completed within the preceding two years .

G. Continuing education requirements for certifying clinicians, practitioners and facilitators: (1) Certifying clinicians: Certifying clinicians shall complete a minimum of eight hours of continuing medical education credits specific to psychedelic medicine or therapy every two years. (2) Practitioners and facilitators: Practitioners and facilitators shall complete a minimum of 20 hours of continuing education credits specific to psychedelic therapy and practice every two years. Practitioners and facilitators shall also keep current with their basic life support, or cardiopulmonary resuscitation and automated external defibrillation certification, or emergency medical technician licensure in addition to the 20 hours of continuing education credits.

H. Waiver of didactic requirements: The department may waive, temporarily suspend, or otherwise reduce the didactic hourly and topic requirements for individuals applying for certification in order to facilitate the certification of individuals trained by other programs, to build the initial infrastructure of the program, or if subsequent evaluations of educational programs determine the changes are appropriate for ensuring competency of the applicants for certification. [7.35.3.18 NMAC - N, xx/xx/2026]

Open The didactic hours, doubled and still contested. The board sent the didactic hours to committee by a 7-0 vote on July 17. The July 23 text set the therapy module at 30 didactic hours with 5 simulated patient hours; this text sets 65 didactic hours, at least one third in person, with 10 simulated patient hours, matching the recommendation's 80-hour total while declining its per-area minimums. The committee's recommendation, at its August 21 position, sets minimums in nine content areas; it is on the recommendation page, and public comment continues through the October 2 hearing.
Note New in this text. Eleven topics enter the required list, legal considerations, cultural competencies, traditional and ceremonial practices, equity and access, informed consent, touch and somatic awareness, and continuity of care among them, none with an hour minimum. A new waiver at Subsection H lets the department reduce the didactic hourly and topic requirements.
Note Drafting slip in the published PDF. Paragraph (2) of Subsection C states its competency-evaluation sentence twice and carries a stray punctuation mark after “five hours”. Quoted as published; the PDF governs.
Defect A module with no date it must exist. Every certification pathway requires a New Mexico module created or approved by the department, and the rule sets no date by which that module must exist. Finding B2.
7.35.3.19

Practicum Requirements For Practitioners And Facilitators

PDF p. 13

A. Minimum practicum hours; administration day sessions: An individual who seeks to become certified as a practitioner or facilitator shall participate in supervised practice training, otherwise referred to as a “practicum”, after completing at least half of the didactic requirements and all of the simulated patient requirements of the educational requirements. The practicum shall consist of a minimum of 100 hours of supervised practice training for facilitators and 120 hours for practitioners which shall be completed prior to applying for certification. Students shall participate in a minimum of 80 hours of administration day sessions, where students are provided the opportunity to experience, observe, or conduct supervised facilitation of in -person administration day sessions with a minimum of 14 different patients over a minimum of eight different administration and same-day sessions with the following criteria: (1) A minimum of six different patients during a minimum of six individual administration day sessions; (2) A minimum of two different group administration day sessions with four or more patients in each group administration day session; and (3) The initial 20 hours of administration day sessions shall be with patients who are determined by the supervising practitioner to be low-risk for adverse events or other complications. (4) Same-day administration sessions shall include patients who have a diversity of the qualifying conditions.

B. Minimum practicum hours; preparation and integration sessions: Students shall participate in a minimum of 20 hours of in-person preparation and integration sessions, where students are provided the opportunity to experience, observe, or conduct (when licensure allows) preparat ion or integration sessions. This shall include a minimum of six different patients during individual sessions. This shall include at least one group preparatory and one group integration session with a minimum of four or more patients.

C. Practicum evaluation: As part of the minimum required practicum hours, the student shall present a minimum of two of the last four patients to the practicum supervisor as case presentations for evaluation, and must receive a passing grade on the case presentations to complete their practicum.

D. Practitioner supervision hours: Practitioners shall complete an additional minimum of 20 hours as a practitioner supervising facilitators during in-person administration day sessions, which shall include a minimum of two different patients during individual administration day sessions, and a minimum of one group administration day sessions with a minimum of four or more patients in the group.

E. Practicum location: All practicum hours shall take place in an approved healing center or other approved location.

F. Practicum standards: Practicum supervisors and students shall follow these rules as they apply to facilitation and therapy, shall comply with HIPAA and HITECH confidentiality requirements, and shall comport with applicable limits on scope of practice.

G. Waiver of practicum requirements: The department may otherwise waive, temporarily suspend, or reduce the practicum requirements for individuals applying for certification, in order to facilitate the certif ication of individuals trained by other government-approved programs, and to build the initial infrastructure of the program.

H. Waiver of practicum hours requirement for applications received by December 31 , 2027: An applicant for certification shall not be required to satisfy the full New Mexico practicum hours requirement if the applicant: (1) Applies for certification by December 31, 2027; (2) Completes the didactic requirements by December 31, 2027; (3) Graduates from an educational program that the department certifies by December 31, 2027 or that the department has included on the department-approved list of educational programs by December 31, 2027; and (4) Demonstrates completion of at least 40 hours of contact time through logs or other records of the sessions, including: (a) A minimum of two separate individual sessions including the appointments for preparation, administration and integration; and (b) A minimum of one group session including the appointments for preparation, administration, and integration. [7.35.3.19 NMAC - N, xx/xx/2026]

Open The practicum totals, published unchanged a second time. The board voted 7-0 on July 17 to send the practicum hours to committee. The July 23 text carried them unchanged, and this text carries them unchanged again: 100 hours for facilitators, 120 for practitioners. The committee's recommendation, at its August 21 position, proposes a staged practicum of 102 hours for facilitators and 114 for licensed providers, the recommendation's name for the role this text calls the practitioner; the two positions can be compared on the working model of the hours.
Note New in this text. Three additions inside the unchanged totals: the first 20 administration-day hours are with patients the supervising practitioner determines to be low-risk, Paragraph (3) of Subsection A; same-day sessions must include patients with a diversity of the qualifying conditions, Paragraph (4); and the student must pass case presentations on two of their last four patients to complete the practicum, Subsection C.
Defect A practicum that requires patients it cannot lawfully use. Subsection A requires a minimum of 14 qualified patients at approved locations, no provision authorizes practicum with non-patients, and the only relief is a discretionary waiver with no stated standard. Finding B4. The provision is quoted, with everything else a practicum change reaches, at 7.35.3.19 (A) on What a practicum change touches.
7.35.3.20

Requirements For Healing Centers And Other Approved Locations

PDF p. 14

A healing center and a registrant of another approved location shall comply with the following requirements:

A. A healing center and a registrant of another approved location shall maintain a list of all qualified patients who have utilized the location for administration sessions.

B. A healing center shall not possess firearms on the healing center’s premises.

C. Medical psilocybin products may only be consumed on the premises of a healing center or other approved location. A healing center and a registrant of another approved location shall not allow the consumption of unauthorized psilocybin products during an administration session. A healing center and a registrant of another approved location shall not promote unregulated cultivation or processing of psilocybin products, and a registrant of another approved location shall not sell psilocybin products that are not lawfully produced or acquired in accordance with department rule.

D. Except in circumstances involving an emergency response, only patients, certified individuals, and students completing their practicums may be present during an administration session unless each patient gives prior written consent for the other individual(s) to be present.

E. A healing center and a registrant of another approved location shall maintain a daily log of all activities related to the purchase, storage, and administration of psilocybin, and shall maintain a copy of information contained in the log within the electronic system designated by the department, and shall provide information to the department upon request in a form and manner designated by the department .

F. A healing center shall publicly display a copy of its certification from the department.

G. A healing center shall provide the following information to qualified patients: (1) Information regarding safe transportation of the qualified patient following an administration session; (2) The healing center’s patient bill of rights and responsibilities; (3) Information explaining informed consent; (4) Information on how to file a complaint with the department or other relevant state entities; and (5) How to report an adverse health event to the department.

H. A healing center and a registrant of another approved location shall create and maintain a safety and emergency plan which: (1) Identifies procedures for evacuating and relocating patients to a safe location if the approved location becomes unsafe; (2) Identifies general procedures for emergency response when a patient experiences a medical or other emergency; (3) Identifies procedures for addressing disruptive conduct and patient reactions that do not rise to the level of requiring an emergency response; (4) Describes how the healing center will address a situation in which a patient attempts to leave an administration session against medical advice; and (5) Includes procedures to ensure that there are practitioners and facilitators present at all times during an administration session with a minimum of one practitioner and one facilitator for individual patient sessions; and in group administration sessions a minimum of one practitioner for every eight patients and a minimum of one facilitator or qualified student for every two patients. For purposes of the foregoing provision, a student shall be deemed qualified to substitute as a facilitator, including for the purpose of billing, if they are registered with a certified educational program and they have completed at least 50 hours of their practicum. Exception: the department may waive or decrease this requirement if the department determines that the ratio specified presents a barrier for patients and that safety concerns are otherwise alleviated.

I. A healing center and a registrant of another approved location shall provide the emergency and safety plan to all persons who utilize the location.

J. In the event that any emergency procedure is utilized, the healing center or registrant of another approved location shall, within two calendar days, submit a report to the department utilizing the electronic system designated by the department, which shall identify whether the procedures of the safety and emergency plan were adhered to, whether there were deviations from the plan, whether the pla n did not work as intended in whole or in part, and what if any procedures the healing center or other approved location intends to modify to ensure safety of individuals in the event of future incidents.

K. A healing center, and a registrant of another approved location, that conducts administration sessions in a natural environment setting that is 15 minutes or more away from emergency medical service response or a hospital, urgent care, or other emergency medical services shall ensure that there is a basic first aid kit and an AED on site, and that there are at least two individuals present during administration sessions who are not receiving treatment and who have: (1) Wilderness first aid certification; (2) Wilderness first responder certification; or (3) Licensure as a New Mexico emergency medical technician (e.g., EMT-basic, EMT- intermediate, EMT-paramedic).

L. All psilocybin products stored at a healing center or other approved location shall be stored within a secure, locked area, which shall be: (1) An area enclosed on all sides with permanent walls and secured with, at a minimum, a properly installed steel door with a steel frame, and utilizing a commercial grade, non -residential lock; (2) A locked safe; or (3) A secure, locked refrigerator or freezer, for products that require refrigeration.

M. A healing center and a registrant of another approved location shall report any potential adverse health event associated with medical psilocybin services to the department no later than two calendar days after the healing center becomes aware of, or is otherwise notified of, the event, using the electronic system designated by the department. Healing centers and registrants of other approved locations shall maintain records of all adverse health event reports in accordance with these rules. Reports of adverse health events shall include: (1) Patient record number; (2) Unique identification number of the product(s) used; (3) Any challenging psychological, emotional, or behavioral reactions; (4) Any participant reaction requiring medical or therapeutic attention; (5) Any incident requiring emergency response; and (6) Any other incident which has a negative impact on a patient.

N. A healing center and a registrant of another approved location shall timely provide the department access to records, upon the department’s request. [7.35.3.20 NMAC, xx/xx/2026]

Note Students in the staffing ratio, now including billing. Paragraph 5 of Subsection H counts qualified students toward staffing ratios once past 50 practicum hours, which is how the department said students would participate instead of a training permit, and the August 25 text adds that the substitution includes the purpose of billing. It depends on the authorization missing from 7.35.3.14. Source: July 17 committee transcript; finding B1.
Note Moved here from the application sections. The natural-environment requirements, two wilderness-certified individuals present and a first aid kit and AED on site when the setting is 15 minutes or more from emergency medical services, were application items in 7.35.3.11 in the July 23 text. The August 25 text makes them an operational duty during administration sessions, Subsection K.
7.35.3.21

Department Evaluation And Assessment Of Psilocybin Educational Programs, Healing Centers, And Other Approved Locations

PDF p. 16

A. Authority to conduct assessments: The department or its designee may conduct remote or on‑site assessments of a psilocybin education program, healing center or other approved location, with or without prior notice, during normal business hours, for the purpose of determining compliance wit h the Medical Psilocybin Act and this rule. In conducting assessments, the department may review documentation, inspect premises and equipment, and interview staff and patients. Exception: except in emergency circumstances, the department or its designee shall not conduct an on-site assessment during a patient session or at a patient’s home without prior written consent from the patient(s).

B. Curriculum implementation review: Educational program assessments may include review and observation of the current curriculum, instructional delivery, and related educational activities to determine whether the curriculum is being implemented with fidelity and in accordance with departme nt requirements.

C. Record retention review: Assessments shall include a review of the certificant or certificant - applicant record retention plan and verification that the plan is being followed in accordance with all applicable requirements.

D. Additional documentation: The department may require any additional documentation it deems reasonably necessary to verify compliance with the Medical Psilocybin Act, this rule, or any other applicable law or regulation. A psilocybin educational program, healing center, or other approved location shall provide requested documentation within the timeframe specified by the department. [7.35.3.21 NMAC - N, xx/xx/2026]

7.35.3.22

Prohibitions And Limitations For Qualified Patients And Certificants

PDF p. 16

Participation in the medical psilocybin program by a qualified patient or certificant does not relieve the qualified patient or certificant from criminal prosecution or civil penalties for:

A. Consumption of psilocybin outside an administration session conducted in accordance with the requirements of this rule;

B. Unlawful distribution, transfer, or use of psilocybin;

C. Operation of a vehicle while under the influence of psilocybin;

D. Transport of psilocybin outside of New Mexico, or transport of psilocybin from another state into New Mexico;

E. Fraudulent representation to a law enforcement officer regarding the person’s participation in the program; or

F. Any other activity not authorized by this rule or the Medical Psilocybin Act. [7.35.3.22 NMAC, xx/xx/2026]

7.35.3.23

Prohibition Against Dual Ownership In Certificant And Permittee

PDF p. 16

A certificant or a person who holds an ownership interest in a certificant shall not hold an ownership interest in a permittee. [7.35.3.23 NMAC, xx/xx/2026]

7.35.3.24

Complaints To The Department

PDF p. 16

A qualified patient or certificant may submit a complaint to the department regarding a certificant in the medical psilocybin program, or regarding any activity or concern related to the medical psilocybin program. The complaint should be in writing, addressed to the medical psilocybin program, and submitted by U.S. certified mail or through the electronic system designated by the department. The department may request additional information for purposes of its own inquiry. A complaint shall include the name and contact information for the complainant; and a statement of the nature of the complaint and any individuals who may be involved. The department may, within its discretion, choose to conduct a subsequent inquiry, and may request additional information from the complainant for this purpose. [7.35.3.24 NMAC, xx/xx/2026]

7.35.3.25

Informal Administrative Review Of Denied Patient Applications

PDF p. 17

A. Administrative review: An applicant for patient enrollment whose application has been denied may request an informal administrative review from the department.

B. Procedure for requesting informal administrative review: (1) An applicant given notice of an application denial, and a patient whose enrollment has been immediately suspended, may submit a request for an administrative review through the electronic system designated by the department or mail a written request to the department. To be effective, the request shall: (a) Be made within 30 calendar days, as determined from the date of the denial notice issued by the department; (b) State the requestor’s name, address, and telephone number; (c) Provide a brief narrative rebutting the circumstances of the application denial or demonstrate that the issues which resulted in the denial have been resolved; and (d) If applicable, provide supplemental documentation from the applicant’s clinician supporting the medical condition as eligible for the program. (2) If the applicant wishes to submit additional documentation for consideration, such additional documentation must be included with the request for an administrative review. (3) A request for administrative review shall not operate to stay or modify the time required for a denied patient applicant to request a formal appeal of the denial pursuant to this rule.

C. Administrative review proceeding: The administrative review proceeding shall be a closed proceeding that is limited to an administrative review of application materials and documents offered to verify eligibility. The administrative review proceeding is not an adjudicatory hearing, and an individual whose initial application for a registry identification number has been denied shall not be entitled to an adjudi catory hearing to contest the denial. The administrative review shall be conducted by the administrative review committee. In cases where the administrative review committee finds the need for additional or clarifying information, the review committee shall request that the applicant supply such additional information within the time set forth in the committee’s request.

D. Final determination: (1) Content and timeline: The administrative review shall be completed, and a decision setting forth the reasons for the decision and the evidence upon which the decision is based, no later than 15 calendar days from the date that the program receives the written request for a record review. (2) Effect: The decision of the administrative review committee is the final decision of the informal administrative review proceeding. (3) Notice: A copy of the decision shall be issued to the applicant via certified U.S. postal mail and posted within the electronic system designated by the department.

E. Judicial review: Except as otherwise provided by law, there shall be no right to judicial review of a decision by the administrative review committee. [7.35.3.25 NMAC, xx/xx/2026]

Note Heading misprint in the published text. The published PDF numbers this section's heading 7.34.3.25. Its own history note and every cross-reference in the rule read 7.35.3.25, which this page uses.
7.35.3.26

Voluntary Withdrawal From Enrollment Or Relinquishment Of Certification

PDF p. 17

A qualified patient may voluntarily withdraw from enrollment in the medical psilocybin program, and a practitioner, certifying clinician, facilitator, healing center or other approved location, or educational program may voluntarily relinquish its certification, at any time, by submitting written notice to the department. Upon receipt of such notice, the department shall terminate the enrollment or certification , which shall be effective on the date that the notice is received by the department. [7.35.3.26 NMAC, xx/xx/2026]

7.35.3.27

Disciplinary Actions And Appeal Process For Enrolled Patients, Patient-Applicants, Certificants, And Applicants For Certification

PDF p. 17

A. Notices of disciplinary action; grounds for disciplinary action: The department may issue a notice of contemplated action to deny, suspend, or revoke, or take other disciplinary action regarding a patient’s enrollment as a qualified patient in the medical psilocybin program, and may deny, suspend, revoke, or take other disciplinary action regarding the certification of a practitioner, certifying clinician, facilitator, healing center or other approved location, or an educational program. The department may also immediately suspend enrollment or certification if the department determines that such action is necessary to protect the health or safety of a patient or the general public. Notice shall be served via certified U.S. postal mail. A notice shall be deemed to have been served on the date borne by the certified mail return receipt showing delivery or the last attempted delivery, or the refusal of the addressee to accept delivery, at their address of record with the program.

B. Grounds for disciplinary action: Disciplinary action may be imposed based on: (1) violation of, or failure to comply with, any provision of this rule or the Medical Psilocybin Act; (2) threatening or harming a patient, practitioner, clinician, facilitator, or an employee of a producer, a laboratory, an educational program, a healing center or other approved location, or the department; (3) intentionally destroying, damaging, altering, removing, or concealing evidence of a violation of rule or statute; attempting to do so; or asking or encouraging another person to do so; (4) conduct that shows willful or reckless disregard for health or safety; (5) falsification or misrepresentation of any material or information submitted to the department; (6) failure to adhere to any attestation, acknowledgement, verification, or other representation made to the department; (7) failure to submit or disclose information required by this rule or otherwise requested by the department; (8) for certifying clinicians and practitioners: any determination by the individual’s licensing body that the clinician has engaged in unprofessional or dishonorable conduct ; (9) for certifying clinicians, practitioners, and facilitators: registration in any jurisdiction as a sex offender.

C. Persons who may request a hearing: The following persons may request a hearing to contest an action or proposed action of the department, in accordance with this rule: (1) a certified patient; (2) a certified practitioner; (3) a certifying clinician who was certified by the department; (4) a certified facilitator; (5) a certified healing center or other approved location; (6) a certified educational program; and (7) an applicant for enrollment or certification as any of the foregoing, whose application is denied for any reason other than failure to submit a completed application or failure to meet a submittal requirement of this rule.

D. Timing and content of request for hearing: A person who has received a notice of contemplated action to impose a disciplinary action or a notice of immediate disciplinary action pursuant to this section who wishes to request a hearing (hereafter, “the appellant”) may do so by mailing a written request for hearing no later than 30 calendar days from the date that the notice of contemplated action is received. The request shall: (1) be properly addressed to the medical psilocybin program; (2) be mailed to the medical psilocybin program via certified U.S. postal mail (return receipt requested, to verify delivery); (3) state the requestor’s name, address, and telephone number; and (4) include a statement of the issue(s) that the requestor considers relevant to the review of the action.

E. Hearing process: (1) All hearings held pursuant to this section shall be conducted by a hearing officer appointed by the secretary. (2) Hearings shall be conducted in Santa Fe, NM, provided that, if the appellant is located more than 100 miles from Santa Fe, NM, or if the parties otherwise consent, the hearing may be conducted via telephone or via web video conference. (3) Hearings held pursuant to this section that concern patients or patient-applicants shall be closed to the public. Hearings may also be closed in whole or in part, upon the request of a party, to prevent the disclosure of other information that is confidential under applicable law. (4) The hearing shall be recorded, at a minimum, by means of sound reproduction.

F. Scheduling: The department shall schedule and hold the hearing as soon as practicable, provided that the hearing shall not be held later than 60 calendar days from the date the department receives the request for hearing. The hearing officer may extend the 60-day time period upon motion for good cause shown, or the parties may extend the 60-day time period by mutual agreement. The department shall issue a notice of hearing, which shall include: (1) a statement of the location, date, and time of the hearing; (2) a short and plain statement of the legal authority under which the hearing is to be held; and (3) a short and plain statement of the subject of the hearing.

G. Presentation of evidence: All parties shall be given the opportunity to present evidence and argument on all relevant issues.

H. Record of proceeding: The record of the proceeding shall include the following: (1) all pleadings, motions, and intermediate rulings; (2) evidence and briefs received or considered; (3) a statement of matters officially noticed; (4) offers of proof, objections, and rulings thereon; (5) proposed findings and conclusions; and (6) any findings or decisions recommended by the hearing officer for adoption by the secretary.

I. Recording: A party may request a copy of the recording of the proceedings.

J. Procedures and evidence: (1) A party may be represented by a person licensed to practice law in New Mexico or a non - lawyer representative, or may represent themselves. (2) The rules of evidence as applied in the courts do not apply in these proceedings. Any relevant evidence shall be admitted. Irrelevant, immaterial, or unduly repetitious evidence may be excluded. (3) The experience, technical competence, and specialized knowledge of the hearing officer, the department or the department’s staff may be used in the evaluation of evidence. (4) An appellant’s failure to appear at the hearing at the date and time noticed for the hearing shall, absent good cause, constitute a default.

K. Conduct of proceeding: Unless the hearing officer determines that a different procedure is appropriate, the hearing shall be conducted in accordance with the procedures set forth in this rule. The following procedures shall apply: (1) the appellant shall present an opening statement and the department may present an opening statement or reserve the statement until presentation of the department’s case; (2) after the opening statements, if made, the appellant shall present their case; (3) upon the conclusion of the appellant’s case, the department shall present its case; (4) upon conclusion of the appellee’s case, the appellant may present rebuttal evidence; and (5) after presentation of the evidence by the parties, the parties may present closing argument.

L. Burden of proof: The appellant shall bear the burden of establishing by a preponderance of the evidence that the decision made or proposed by the department should be reversed or modified.

M. Continuances: The hearing examiner may grant a continuance for good cause shown. A motion to continue a hearing shall be made at least 10 calendar days before the hearing date.

N. Telephonic and web video hearings: (1) Any party requesting that a hearing be conducted via telephone or web video conference shall do so no less than 10 business days prior to the date of the hearing. Notice of the hearing shall be given to all parties and shall include all necessary telephone numbers or instructions for access to the web video conference. (2) The in-person presence of some parties or witnesses at the hearing shall not prevent the participation of other parties or witnesses by telephone or web video conference with prior approval of the hearing officer.

O. Recommended action and final decision: (1) The parties may submit briefs including proposed findings of fact and conclusions of law for consideration by the hearing officer. (2) No later than 30 calendar days after the last submission by a party, the hearing officer shall prepare and submit to the secretary a written recommendation of action to be taken by the secretary. The recommendation may include proposed findings of fact and conclusions of law for adoption by the secretary, and shall propose sustaining, modifying, or reversing the action or proposed action of the department. (3) The secretary shall issue a final written decision accepting or rejecting the hearing officer’s recommendation in whole or in part no later than 45 calendar days after receipt of the hearing officer’s recommendation. The final decision shall identify the final action taken. Service of the secretary’s final decision shall be made upon the appellant via certified U.S. postal mail. (4) The final decision or order shall be included in a medical psilocybin program’s file concerning the petitioner. [7.35.3.27 NMAC - N, 9/22/2026]

7.35.3.28

Severability

PDF p. 20

The provisions of this rule are separate and severable. If any provision of this rule is held to be invalid, unconstitutional, or unenforceable, the remaining provisions shall stay in effect. [7.35.3.28 NMAC - N, 9/22/2026]

Provenance: the source document and this page’s revisions

The document this page is read from

August 25, 2026

Revised proposed ruleCurrent state of truth

The revised proposed rule, published August 25 with the notice fixing the October 2 hearing, superseding the set-aside July 23 text. Raised the practitioner and facilitator therapy module from 30 didactic hours to 65, at least one third in person, and the simulated patient requirement from 5 hours to 10. Added eleven curriculum topics without per-area hour minimums, a case-presentation evaluation inside the unchanged 100 and 120 practicum hours, a low-risk requirement on the first 20 administration-day hours, and a didactic waiver. Kept the role names certifying clinician and practitioner, defining them in amendments to 7.35.2.7 published the same day.

This document supersedes four earlier ones. Each of them, what it is, what superseded it and when, and a download, is in the register at Meetings and filings.

Revisions to this page

  • August 26, 2026 Two definitions notes entered: the clinician definition does not cover the certifying clinician, whose subtype it anchors, because it reaches only the three-session medical services; and the qualified-patient definition substitutes certifying clinician where the Medical Psilocybin Act's own definition says clinician, placing the statutory appropriateness judgment in the number-holding role.
  • August 26, 2026 An open note entered at 7.35.3.11: the other-approved-location application requires proof of ownership or a signed statement from the property owner acknowledging program participation on the premises, so a renting patient needs the landlord's signature to be treated at home, with the landlord-approval and privacy question raised at the August 21 committee meeting noted.
  • August 26, 2026 A definitions section entered between 7.35.3.7 and .8, generated from the amendments extraction: the twenty-five program-side definitions of the amended 7.35.2.7 verbatim in the amendment's own strike-and-add notation, each cited to its page, with notes on the contested certifying-clinician scope, the rewritten practitioner, the struck guide, and where the qualifying conditions bind the curriculum.
  • August 26, 2026 Regenerated from the August 25 extraction by tools/build-rule-page.py, whose chrome was brought current so the generator runs again instead of being mirrored by hand: all twenty-eight sections of the revised text, the annotations rewritten for what changed, the four heading misprints corrected in the text and the one that persists noted at 7.35.3.25.
  • August 24, 2026 Reframed as the last published text: the July 23 publication and its August 28 hearing were set aside, and the kicker and lede state the set-aside. The annotation notes at 7.35.3.18 and .19 now state the recommendation at its August 21 position, 80 didactic hours and a staged practicum of 102 or 114, in place of the July 27 figures; mirrored into tools/build-rule-page.py. The text is unchanged.
  • August 21, 2026 The kicker now states the schedule as restated: the department stated at the August 21 committee meeting that revised proposed rules publish August 25 and that the rule hearing, first set for August 28, is anticipated for October 2, with the final notice to fix the date. Mirrored into tools/build-rule-page.py, which owns this page.
  • July 28, 2026 The defect notes that name findings B1, B4, and B5 now link those findings on What a practicum change touches, so a named cross-reference no longer asks the reader to go search. The links were mirrored into the page by hand because tools/build-rule-page.py, which owns this page, still carries retired chrome; the generator now refuses to run until that is brought current, rather than silently replacing the shared menu and the visit counter. The page name is now the same in the title, the heading, and the menu: the published rule.
  • July 28, 2026 One grouped menu on every page replaced the flat seven-item navigation, with the Documents dropdown at its right edge, and every stylesheet link now carries the style.css content hash so a page and its styles arrive from the same deploy.
  • July 27, 2026 Created in the July 27 redesign, generated from the published extraction by tools/build-rule-page.py: all twenty-eight sections verbatim, with the state of each contested provision, the five defect notes, and the heading misprints noted at the provision they belong to. Citations open on hover, close on leave, and open the source in a new tab on click. The annotations moved into the generator the same day, so regeneration keeps them, and the submitted recommendation's figures entered the annotations with them.